Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Goodwill & Intangibles: 2012-2024

Historic Goodwill & Intangibles for Ani Pharmaceuticals (ANIP) over the last 13 years, with Dec 2024 value amounting to $601.8 million.

  • Ani Pharmaceuticals' Goodwill & Intangibles fell 10.78% to $562.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $562.3 million, marking a year-over-year decrease of 10.78%. This contributed to the annual value of $601.8 million for FY2024, which is 153.69% up from last year.
  • Ani Pharmaceuticals' Goodwill & Intangibles amounted to $601.8 million in FY2024, which was up 153.69% from $237.2 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Goodwill & Intangibles high stood at $601.8 million for FY2024, and its period low was $192.1 million during FY2020.
  • Moreover, its 3-year median value for Goodwill & Intangibles was $279.9 million (2022), whereas its average is $373.0 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Goodwill & Intangibles surged by 175.04% in 2021 and then crashed by 47.04% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Goodwill & Intangibles (Yearly) stood at $192.1 million in 2020, then surged by 175.04% to $528.4 million in 2021, then crashed by 47.04% to $279.9 million in 2022, then dropped by 15.23% to $237.2 million in 2023, then surged by 153.69% to $601.8 million in 2024.